pioneer 6 oral semaglutide cardiovascular outcomes trial results Efficacy, safety and of once‐daily in patients with type 2 diabetes: The programme - Thethi - 2020 - Diabetes, Obesity and Metabolism Cardiovascular Outcomes Trial (CVOT) |

Sustainability after stopping the medication depends heavily on the behavioral and lifestyle changes established during treatment

L.FengQ.LiS.LiangS.et al (2017)

If you carry certain FTO or MC4R variants associated with higher appetite drive, you may benefit from more aggressive semaglutide dosing or a combination therapy like GLP-Squared (which combines semaglutide and tirzepatide)

More specifically, both RCTs with paired liver biopsies showed improvement in hepatic steatosis and inflammation, but not fibrosis, after treatment with liraglutide or semaglutide

BMI between 27 and 29.9 qualifies with a weight-related comorbidity

Your provider will need to review your current dose, last injection date, side-effect history, blood sugar levels, weight-loss progress, and new starting dose before making the switch